Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription


1 Br J Cancer
1 Br J Dermatol
3 J Am Acad Dermatol
1 J Clin Oncol
1 J Invest Dermatol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Br J Cancer

  1. BOUCHEREAU S, Chaplain L, Fort M, Beauchet A, et al
    Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01486.
    PubMed         Abstract available

    Br J Dermatol

  2. STOER NC, Botteri E, Busund M, Ghiasvand R, et al
    Menopausal hormone therapy and risk of melanoma: a population-based cohort study.
    Br J Dermatol. 2021 Jul 13. doi: 10.1111/bjd.20640.
    PubMed         Abstract available

    J Am Acad Dermatol

  3. BUI AN, Bougrine A, Buchbinder EI, Giobbie-Hurder A, et al
    Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: a retrospective cohort study.
    J Am Acad Dermatol. 2021 Jul 9. pii: S0190-9622(21)02087.

  4. STRAKER RJ 3RD, Thaler AS, Shannon AB, Miura JT, et al
    Acral lentiginous melanoma in the era of immune checkpoint blockade and targeted therapy: A National Cancer Database analysis.
    J Am Acad Dermatol. 2021 Jul 9. pii: S0190-9622(21)02095.

    August 2021: On the epistemology of Breslow thickness and histopathologic melanoma subtype.
    J Am Acad Dermatol. 2021;85:318.

    J Clin Oncol

  6. DIAB A, Tykodi SS, Daniels GA, Maio M, et al
    Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
    J Clin Oncol. 2021 Jul 13:JCO2100675. doi: 10.1200/JCO.21.00675.
    PubMed         Abstract available

    J Invest Dermatol

  7. QUADRI M, Comitato A, Palazzo E, Tiso N, et al
    Activation of PKG restricts melanoma growth and invasion by interfering with the EGF/EGFR pathway.
    J Invest Dermatol. 2021 Jul 12. pii: S0022-202X(21)01420.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.